Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol
- 141 Downloads
Elevated levels of triglycerides are associated with pancreatitis and an increased risk of coronary heart disease. Numerous pharmacologic therapies are available to treat hypertriglyceridemia, including prescription omega-3 fatty acids, which reduce triglyceride levels by 20–50%. Available data indicate the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may be beneficial for secondary prevention of coronary heart disease. Products containing DHA may increase low-density lipoprotein cholesterol (LDL-C) and, subsequently, coronary heart disease risk. We reviewed prescription omega-3 fatty acid products, of which two—omega-3 acid ethyl esters (OM3EE) and omega-3 carboxylic acid (OM3CA)—contain both DHA and EPA, whereas the other—icosapent ethyl (IPE)—contains EPA only. We identified three retrospective chart reviews and three case reports comparing IPE with OM3EE, whereas two studies compared IPE with placebo. We also reviewed the major studies of OM3EE versus placebo used to gain US FDA approval. LDL-C levels decreased or did not increase significantly in all available studies and case reports in patients receiving the IPE product, with the best data supporting a dose of 4 g per day. The majority of studies only included patients taking IPE concomitantly with statins, but limited data from one study using IPE monotherapy showed a small reduction in LDL-C. Many questions remain regarding IPE, including whether the product reduces cardiovascular events and mortality.
Compliance with Ethical Standards
Conflicts of interest
Randall P. Sharp, Barry J. Gales, and Riaz Sirajuddin have no conflicts of interest.
No sources of funding were used to assist with the preparation of this review.
- 1.Cohen JD, Cziraky MJ, Cai Q, Wallace A, Wasser T, Crouse JR, Jacobson TA. 30-Year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006 [published correction appears in Am J Cardiol. 2010;106:1826]. Am J Cardiol. 2010;106:969–75.CrossRefPubMedGoogle Scholar
- 3.Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S1–45.CrossRefPubMedGoogle Scholar
- 5.Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e867–84. https://doi.org/10.1161/CIR.0000000000000482.CrossRefPubMedGoogle Scholar
- 6.Lovaza® [package insert]. GlaxoSmithKline, Inc., Research Triangle Park, NC, USA; 2015.Google Scholar
- 7.Omtryg®[package insert]. Trygg Pharma, Inc., Arlington, VA, USA; 2016.Google Scholar
- 10.Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92. https://doi.org/10.1016/j.amjcard.2012.05.031.CrossRefPubMedGoogle Scholar
- 11.Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial. Am J Cardiol. 2011;108:682–90. https://doi.org/10.1016/j.amjcard.2011.04.015.CrossRefPubMedGoogle Scholar
- 12.Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–67. https://doi.org/10.1016/j.clinthera.2007.07.018.CrossRefPubMedGoogle Scholar
- 13.Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35(9):1400–11. https://doi.org/10.1016/j.clinthera.2013.07.420.CrossRefPubMedGoogle Scholar
- 30.Vascepa® [package insert]. Amarin Pharmaceuticals, Inc., Bedminster, NJ, USA; 2012.Google Scholar
- 31.Shannon R, John S, Ferrera J, Best S, Allen SN. Statin-associated myopathy. US Pharm. 2012;37(2):55–9.Google Scholar
- 32.Amarin (2017) Amarin announces publication of REDUCE-IT cardiovascular outcomes study rationale and design in clinical cardiology. http://investor.amarincorp.com/releasedetail.cfm?releaseid=1017519. Accessed 26 Oct 2017.